David Maguire, Ph.D.
Drug abuse remains a significant public health problem. Many factors contribute to the development and maintenance of drug taking, and understanding these factors will aid in the improvement of prevention and treatment of drug abuse. Our laboratory uses a variety of techniques to study interactions between behavior and pharmacology, with a focus on how those interactions contribute to the therapeutic and abuse-related effects of drugs. Current areas of interest include (1) evaluating novel pharmacotherapies for opioid and stimulant abuse; (2) characterizing effects of drug combinations, particularly combinations that might have therapeutic potential such as treating pain; and (3) examining effects of repeated treatment with drugs of abuse (e.g., opioids) on choice, decision making, and impulsivity.
University of Florida
|• drug abuse||• choice|
|• decision making||• impulsivity|
|• neuropharmacology||• drug dependence|
Awards & Accomplishments
NIDA Travel Award to the International Narcotics Research Conference (Bath, United Kingdom) – 2016
ASPET Young Scientist Travel Award – 2016
UTHSCSA Department of Pharmacology Chair’s Award for Excellence in Research – 2015
ASPET Young Scientist Travel Award – 2015
ASPET James A. Bain Young Scientist Travel Award to the World Congress of Basic and Clinical Pharmacology (Cape Town, South Africa) – 2014
ASPET Young Scientist Travel Award – 2014
CPDD NIDA Director’s Travel Award – 2014
Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Training Fellow (F32) – 2013-14
NIDA Director’s CPDD Travel Award – 2013
ASPET Young Scientist Travel Award – 2013
NRSA Postdoctoral Training Fellow (T32) – 2011-2013
Behavioral Pharmacology Society
International Study Group Investigating Drugs as Reinforcers
American Society for Pharmacological and Experimental Therapeutics (ASPET)
Association for Behavior Analysis
College on Problems of Drug Dependence
Maguire DR, Gerak LR, Woods JH, Husband SM, Disney A, and France CP (2018) Long-lasting effects of the pseudo-irreversible mu opioid receptor antagonist methocinnamox on remifentanil versus food choice in rhesus monkeys. American College of Neuropsychopharmacology, Hollywood, FL.
Maguire DR, Gerak LR, Woods JH, Husband SM, Disney A, and France CP (2018) The novel, pseudo-irreversible mu opioid receptor antagonist methocinnamox attenuates the reinforcing and respiratory-depressant effects of heroin in rhesus monkeys. World Congress of Basic and Clinical Pharmacology, Kyoto, Japan.
Gerak LR, Maguire DR, Woods JH, Husbands SM and France CP (2018) A novel, long-lasting µ opioid receptor antagonist prevents and reverses the respiratory-depressant effects of heroin in rhesus monkeys. ASPET, San Diego, CA.
Maguire DR and France CP (2018) Demand analysis of the mu opioid receptor agonist remifentanil alone and in combination with the cannabinoid receptor agonist JWH018. ASPET, San Diego, CA.
Dodda V, Maguire DR, Minvervini V and France CP (2018) Order of fixed-ratio presentation does not impact demand for the opioid remifentanil. Behavior, Biology, and Chemistry, San Antonio, TX.
Lectures and Presentations
Maguire DR, Gerak LR, Woods JH, Husbands SH, Disney A, and France CP (2018) Sustained decreases in opioid self-administration in rhesus monkeys after a single administration of methocinnamox. College on Problems of Drug Dependence, San Diego, CA.
Maguire DR (2017) Exploring the therapeutic potential of opioid/cannabinoid mixtures. University of Texas Health Science Center at San Antonio, Department of Pharmacology Seminar Series.
Maguire, DR., Weed, PF., Gerak, LR. and France, CP. (2017) Assessing therapeutic and abuse potential of opioid/cannabinoid mixtures in nonhuman primates. Winter Conference on Brain Research, Big Sky, MT.
Maguire, DR. (2016) Exploring the link between impulsivity and drug abuse using choice procedures. Mid-American Association for Behavior Analysis, Wisconsin Dells, WI.
Maguire, D.R. and France, C.P. (2015) Interactions between the discriminative stimulus effects of mu opioid receptor agonists and cannabinoid receptor agonists. Association for Behavior Analysis, San Antonio, TX.
Maguire, D.R., Henson, C., and France, C.P. (2015) Effects of daily morphine treatment on impulsivity in rats responding under a 5-choice serial reaction time task. ASPET, Boston, MA.
Maguire, D. R., Gerak, L.R. and France, C. P. (2014, February) Impulsivity and drugs of abuse. Texas Research Society on Alcoholism, San Antonio, TX.
Maguire DR and France CP (accepted for publication 22 January 2019) Effects of amphetamine, methylphenidate, atomoxetine, and morphine in rats responding under an adjusting stop signal reaction time task. Psychopharmacology
Gerak LR, Collins GT, Maguire DR, and France CP (2019) Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys. Experimental and Clinical Psychopharmacology 27: 78-86. doi:10.1037/pha0000234
Gerak LR, Maguire DR, Woods JH, Husbands SM, Disney A, France CP (2019) Reversal and prevention of the respiratory-depressant effects of heroin by the novel µ opioid receptor antagonist methocinnamox in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics. 368: 229-236. doi:10.1124/jpet.118.253286
Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP (2019) Long-lasting effects of methocinnamox on opioid self-administration in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 368: 88-99. doi:10.1124/jpet.118.252353
Maguire DR and France CP (2018) Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology 235: 2357-2365. doi:10.1007/s00213-018-4932-6